Pfizer sues Metsera, Novo Nordisk
Digest more
NEW YORK, November 03, 2025--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against ...
For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results